Best Stock to Buy Right Now: Costco vs. Kohl's
Investing in retail stocks presents challenges.
Costco sells at a premium valuation.
Kohl's missteps have resulted in a low valuation.
10 stocks we like better than Costco Wholesale ›
Buying stocks in the retail sector can prove tricky. That's because a lot of things can happen quickly, such as changing consumer tastes, a failure of the retailer to adapt, or missteps that prove difficult to overcome.
It's important to keep those factors in mind when analyzing companies in the sector. Costco Wholesale (NASDAQ: COST) and Kohl's (NYSE: KSS) have both been around for a long time, but their results and stock prices have gone in different directions.
Can Costco keep the momentum going, or does Kohl's represent an opportunity to buy the shares at an attractive valuation?
Costco
Most people have heard about Costco. It's become widely known for its spacious warehouses that sell items in bulk. The company charges people an annual fee to shop at its clubs, and members receive a very large array of goods and services at attractive unit prices.
That may sound simple, but Costco has been executing the concept very well for a long time. You can see the proof in renewal rates, which have consistently hovered at about 90% for a long time. In the fiscal third quarter, which ended May 11, renewal rates were 92.7% in the U.S. and Canada.
They've remained high despite Costco implementing an increase in the annual membership (the first time in seven years) at the start of the fiscal year. Clearly, shoppers still find the membership valuable.
Memberships continue to grow. There were 79.6 million paid members at the end of the third quarter, up from 76.2 million as of Sept. 1, 2024.
With this success, Costco continues to expand. It had 905 warehouses at the end of May compared to 890 at the start of the year. Management typically opens 20 to 30 clubs per year.
Fortunately, the expansion doesn't come at the expense of profitability. Its third-quarter operating income grew 15.2% to $2.5 billion.
Naturally, this success isn't lost on investors. The share price has gained 203.8% over the last five years through July 14, handily outpacing the S&P 500 index's 98.7%.
The market expects continued profitability growth. Costco's stock has a price-to-earnings (P/E) ratio of 56 compared to 30 for the S&P 500.
Kohl's
Kohl's offers moderately priced merchandise across various categories like apparel, footwear, beauty, and home products. The offerings don't seem to be hitting the mark since the retailer has seen sales and profits sag for some time, however.
Over the years, management has attempted to boost traffic and sales through various initiatives like integrating Sephora beauty shops at Kohl's retail locations and providing a place to return Amazon merchandise.
Nonetheless, these steps haven't boosted the top line. Fiscal 2024 same-store sales (comps) dropped 6.5%, and earnings per diluted share fell about 47% to $1.50. This covered the period that ended on Feb. 1. This fiscal year got off to a rough start with comps falling 3.9%.
Can management pull off a turnaround, allowing patient investors to prosper? Certainly, management doesn't foresee a quick turnaround. It projects this year's comps will drop 4% to 6%, and diluted earnings per share (EPS) will fall to $0.10 to $0.60.
Additionally, the company has cycled through CEOs, with its latest, Ashley Buchanan, getting terminated after only a few months in the role. The lack of stable leadership makes it tough to create and execute a long-term turnaround strategy.
Earlier this year, the board of directors slashed the quarterly dividend to $0.125 from $0.50 a share. That typically doesn't indicate a company's confidence it its future.
Over the last five years, the share price has lost more than 55%. The stock has a P/E multiple of 9.
The selection
Clearly, Costco is the better-run company. It's been executing well for a very long time, and growth opportunities remain. While the valuation looks rich, and certainly more expensive than Kohl's, I'd rather pay a premium for a well-run company.
Despite the valuation, I'd stay away from Kohl's since a turnaround seems unlikely right now.
Should you invest $1,000 in Costco Wholesale right now?
Before you buy stock in Costco Wholesale, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Costco Wholesale wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $674,281!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,050,415!*
Now, it's worth noting Stock Advisor's total average return is 1,058% — a market-crushing outperformance compared to 179% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of July 15, 2025
John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Lawrence Rothman, CFA has positions in Costco Wholesale. The Motley Fool has positions in and recommends Amazon and Costco Wholesale. The Motley Fool has a disclosure policy.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
26 minutes ago
- Globe and Mail
3 Unstoppable Dow Dividend Stocks to Buy and Hold Forever
Key Points Artificial intelligence (AI) is boosting income and growth at networking giant Cisco Systems. McDonald's, with nearly a half-century of rising dividends, will continue to enrich investors. Challenges in the health insurance industry have boosted the dividend yield at UnitedHealth. 10 stocks we like better than Cisco Systems › The Dow Jones Industrial Average comprises 30 blue chip stocks that investors often regard as a proxy for the overall economy. Amidst that prominence, all but two of the 30 components return cash to shareholders, a move that tends to affirm that stability. Still, investors may also want stock growth potential along with a strong dividend. To that end, these Dow stocks are well-positioned to deliver rising payouts without compromising potential returns from stock price growth. 1. Cisco Systems After years of slow revenue increases, growth is finally speeding up for Cisco Systems (NASDAQ: CSCO). Coming off the networking giant's acquisition of Splunk, product orders are up 20% year over year (or 9% if not including Splunk). The growth comes as companies work to integrate AI into security and network management. The rising orders should also bolster what has already served as a strong dividend. Its payout has risen every year since the company began offering dividends in 2011. At $1.64 per share annually, Cisco now has a dividend yield of 2.4%. That compares well to the S&P 500 's average yield of 1.2%. More importantly, Cisco can likely sustain its dividend growth. In the first nine months of fiscal 2025 (ended April 26), it generated $9.3 billion in free cash flow, enough to cover the $4.8 billion in dividend costs over that period. Investors have begun to take notice of the stock in recent months. The stock is up by nearly 50% over the last year, and its P/E ratio of 28 sits at multi-year highs. Despite that recent growth, that places the P/E ratio slightly under the S&P 500 average earnings multiple of 30, indicating there is likely still time to buy Cisco stock. 2. McDonald's Dividend investors may also find a lot to like in McDonald's (NYSE: MCD) stock. Admittedly, that might not seem to be the case amid a sluggish economy and intense competition in the restaurant industry, and some investors may be leery of its 27 P/E ratio. However, since McDonald's actually profits from franchising, such challenges may have relatively little effect on its top line. McDonald's earns most of its revenue from franchising fees and restaurant rentals from its extensive real estate portfolio. While it also claims a percentage of the revenue driven from these restaurants, it also means that restaurant sales have less of an effect on the company than rivals such as Chipotle Mexican Grill. That stability contributes to the strength of its dividend, which has risen every year since its introduction in 1976. At $7.08 per share annually, it yields 2.3%. Furthermore, the payout appears sustainable, as its more than $6.7 billion in free cash flow covered the dividend costs of about $4.9 billion in 2024. Additionally, the stock was up just over 20% over the last year. When combining that with returns on the dividend, investors appear to have a surprisingly robust growth and income stock in McDonald's. 3. UnitedHealth Group When it comes to Dow dividend stocks, investors may have a unique buying opportunity in health insurer UnitedHealth Group (NYSE: UNH). The company offers health insurance to individuals, including Medicare and Medicaid recipients, as well as plans for employers. Nonetheless, its stock has fallen by nearly 40%, as rising medical costs led to lower earnings guidance in the first quarter of 2025. The tragic shooting of CEO Brian Thompson also plagued the stock. Moreover, investigations by the Department of Justice and The New York Times have called some of its business practices into question. So severe was the drop in the stock price that the selling has wiped out almost all the stock's five-year gain. Although such challenges tend to weigh on stocks, at least for a time, UnitedHealth should be positioned for recovery if it properly addresses those allegations. Additionally, the company's current stock price gives investors a tremendous incentive to take a position in the stock. Its P/E ratio has fallen to 13, its lowest point since 2013. The decline has also boosted its dividend yield to 2.8%, close to all-time highs. With that, it is worth noting that the payout has risen for 15 straight years and now pays shareholders $8.84 per share annually. Furthermore, despite rising costs, UnitedHealth's nearly $21 billion in free cash flow enabled it to meet its $7.5 billion in dividend costs in 2024. Hence, not only can UnitedHealth afford its generous, rising dividend, but investors also have a unique opportunity to buy this stock at an unusually low price. If one can tolerate its risks, the health insurance stock offers tremendous potential for growth. Should you invest $1,000 in Cisco Systems right now? Before you buy stock in Cisco Systems, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Cisco Systems wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $674,281!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,050,415!* Now, it's worth noting Stock Advisor's total average return is 1,058% — a market-crushing outperformance compared to 179% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 Will Healy has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Chipotle Mexican Grill and Cisco Systems. The Motley Fool recommends UnitedHealth Group and recommends the following options: short June 2025 $55 calls on Chipotle Mexican Grill. The Motley Fool has a disclosure policy.
Globe and Mail
26 minutes ago
- Globe and Mail
Royalty Pharma Declares Third Quarter 2025 Dividend
NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on September 10, 2025, to shareholders of record at the close of business on August 15, 2025. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma's current portfolio includes royalties on more than 35 commercial products, including Vertex's Trikafta, GSK's Trelegy, Roche's Evrysdi, Johnson & Johnson's Tremfya, Biogen's Tysabri and Spinraza, AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Novartis' Promacta, Pfizer's Nurtec ODT and Gilead's Trodelvy, and 16 development-stage product candidates. For more information, visit
Globe and Mail
26 minutes ago
- Globe and Mail
3 Crypto Stocks to Watch as the House Passes the GENIUS Act
The U.S. House of Representatives passed the GENIUS Act on July 17, 2025, sending it to President Trump's desk, where it is expected to be signed into law. This landmark legislation establishes the very first comprehensive federal framework for U.S. dollar-pegged stablecoins, placing them under the oversight of the Commodity Futures Trading Commission ('CFTC'). The bill also sets in motion new rules governing issuers, reserves and consumer disclosure, signaling a major regulatory shift. By mandating that stablecoin issuers should back every digital token one-to-one with U.S. dollars, Treasury deposits, or short-term Treasuries, the law aims to put an end to opaque reserve practices. These assets will need to be stored in segregated accounts, undergo regular audits and submit monthly disclosures. Consequently, shares of Galaxy Digital GLXY, Robinhood Markets, Inc. HOOD and Riot Platforms, Inc. RIOT jumped on broader positive momentum in the stablecoin segment. Additionally, the Act extends U.S. jurisdiction to foreign issuers offering stablecoins to American users and prohibits algorithmic stablecoins from qualifying as "payment stablecoins." Traditional financial institutions already have some skin in the game as well. JPMorgan, Bank of America, Citi, Walmart and Amazon have reportedly begun exploring stablecoin issuance to reduce transaction costs, sparking a surge of institutional momentum. At the same time, voices of caution highlight that the Act stops short of offering FDIC protection to stablecoin holders and caps stablecoin issuers from paying interest directly. This nuance may introduce new fee layers and redemption risks even under tighter oversight. In essence, the GENIUS Act brings transformative clarity to stablecoin markets. It lays the groundwork for mainstream adoption, reduces regulatory uncertainty and positions the United States to lead in digital payment systems. But as regulators move quickly, stakeholders across the industry will be watching with a keen eye, ready to adapt to the operational and compliance demands ahead. The reaction in crypto markets was swift. Bitcoin (BTC) and Ethereum (ETH) have held onto near-record highs, while shares of crypto-exposed firms jumped following the House vote. Analysts attribute this surge to a newly found sense of clarity. Institutional and retail investors now have a defined set of rules to follow. A few of them, the ones listed below, must be closely watched for further developments in the sector. Galaxy Digital engages in the digital asset and blockchain businesses. It provides institutional custody, staking services and asset management aligned with compliant stablecoin frameworks. The Zacks Consensus Estimate for its current-year earnings has improved 69.3% over the past 60 days. GLXY is a Rank #3 (Hold) company. Its stock soared 6.9% on the passage of the Act. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Robinhood Markets is a financial services platform. It gained 2.1% post bill passage due to its crypto trading exposure, though stablecoins aren't its core business The Zacks Consensus Estimate for its current-year earnings has improved 7.4% over the past 60 days. HOOD is a Rank #1 company. Its stock soared 6.9% on the passage of the Act. Riot Platforms is a Bitcoin mining and engineering company. Its stock jumped 6.1% on the news, riding broader crypto optimism tied to anticipated broader crypto legislation. The Zacks Consensus Estimate for its current-year earnings has improved 2% over the past 60 days. RIOT is a Rank #3 company. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include Stock #1: A Disruptive Force with Notable Growth and Resilience Stock #2: Bullish Signs Signaling to Buy the Dip Stock #3: One of the Most Compelling Investments in the Market Stock #4: Leader In a Red-Hot Industry Poised for Growth Stock #5: Modern Omni-Channel Platform Coiled to Spring Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%. Download Atomic Opportunity: Nuclear Energy's Comeback free today. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Riot Platforms, Inc. (RIOT): Free Stock Analysis Report Robinhood Markets, Inc. (HOOD): Free Stock Analysis Report Galaxy Digital Inc. (GLXY): Free Stock Analysis Report
